Meeting
2022 ASCO Genitourinary Cancers Symposium
SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
Authors
Michiel Simon Van Der Heijden
Netherlands Cancer Institute, Amsterdam, Netherlands
Michiel Simon Van Der Heijden , Christopher Cutie , Shalaka Hampras , Charu Indoria , Rachel Stewart , Milin Acharya , Katherine Stromberg , Xiang Li , Neil Beeharry , John Maffeo , Joseph M Jacob
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04640623
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr TPS593)
DOI
10.1200/JCO.2022.40.6_suppl.TPS593
Abstract #
TPS593
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
First Author: Joseph M Jacob
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2019 Genitourinary Cancers Symposium
Association of the commensal urinary microbiome with response to Bacillus Calmette-Guérin (BCG) immunotherapy in nonmuscle invasive bladder cancer.
First Author: Randy F. Sweis
Poster
2016 ASCO Annual Meeting
KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).
First Author: Ashish M. Kamat